Among cancer patients, sLAG3 has been reported in three studies to associate with more advanced disease, with higher levels associating with an advanced cancer stage in hepatocellular carcinoma [51] and clear cell renal cell carcinoma [153], and the presence of cervical lymph node metastasis in patients with differentiated thyroid carcinoma [56]. Here, LAG3 is linked to differentiated thyroid carcinoma.